Amgen Inc

Amgen discovers, develops, and sells biologic drugs focused on serious illnesses where patient populations are large enough to support the high costs of biopharmaceutical development. Key franchises include Enbrel and Otezla for inflammation, Prolia and Evenity for bone health, Repatha for cardiovascular disease, and biosimilars of competitor drugs. The company generates revenue primarily through direct sales to hospitals, clinics, and specialty pharmacies in developed markets, with manufacturing concentrated in its own facilities to maintain quality control over complex protein-based medicines.

Amgen combines mature cash-generating products with a mid-stage pipeline targeting obesity, cancer, and inflammation. The stock trades at modest valuation multiples for biotech and returns substantial cash through dividends and buybacks. Key risks include patent expirations on major drugs, biosimilar competition eroding Enbrel revenue, and pipeline execution uncertainty particularly around obesity candidate MariTide. Profitability metrics are strong with operating margins above 40%, but revenue growth has been sluggish in recent years.

In inflammation, AbbVie (Humira, Skyrizi) and Johnson & Johnson (Stelara, Tremfya) compete directly. Regeneron rivals Amgen in cardiovascular with Praluent competing against Repatha. Eli Lilly and Novo Nordisk are major threats in the obesity space where Amgen's MariTide will launch into an established market. In biosimilars, Amgen competes with specialized manufacturers like Sandoz and Samsung Bioepis.

Amgen has paid and grown its dividend for over a decade, with the current yield near 2.7% ranking among the highest in large-cap biotech. The company frames its dividend as a core capital allocation priority supported by predictable cash flows from mature products. Management has maintained dividend growth even during patent cliff periods, though the payout ratio has risen. Strong free cash flow supports both the dividend and substantial share repurchases.

AMGN last closed at $353.93, up 1.58% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $261.43 and a high of $391.29. The current price represents 71% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 42 analysts covering AMGN, the consensus rating is Hold — 21 rate it a buy, 18 hold, and 3 sell. The average price target sits at $190.87, implying 46% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Amgen Inc generated $36.66B in revenue during fiscal year 2026, with $7.69B reaching the bottom line as net income. The net profit margin of 21.0% is strong by most industry standards.

AMGN trades at a P/E ratio of 24.39 on trailing earnings of $14.23 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Biotechnology sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +6.31% (3M), +29.19% (6M), +15.77% (1Y), +8.02% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether AMGN is outperforming or lagging the broader market.